-
Mashup Score: 0
Background: The frequency of HER2 expression in solid tumors other than breast (BC) and gastric cancer (GC) is not well defined. This study describes the frequency of HER2 expression by correlating HER2 IHC/ ISH and ERBB2 mRNA levels by NGS in tumor samples of patients with locally advanced/metastatic (LA/m) BC or GC and applying those findings … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Background Oncogenic BRAF mutations can be categorized into three classes (I, II and III) based on their distinct structural and signaling properties. BRAF inhibitors are approved in select cancer types for patients with Class I mutations. However, there are no approved targeted therapies for patients whose tumors bear BRAF Class II or III mutations. This … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Real-world clinical genomic analysis of Pts w/ BRAF mut cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson etal @ESMO TAT 2022 @TempusLabs https://t.co/s5PEBEczlv @Annals_Oncology DOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx https://t.co/m18RVCkTMF
-
-
Mashup Score: 1Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy - Tempus - 3 month(s) ago
Background: Clonal Hematopoiesis (CH) is a well established confounder in next-generation sequencing (NGS)-based liquid biopsy cancer diagnostics. Misclassification of CH variants as tumor variants can lead to false positive actionable variant detection, potentially resulting in incorrect interpretation of results and therapy selection. Moreover, CH variants may also interfere with quantitative variant monitoring leading to inaccurate … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy [Mar 22, 2024] Sonnenschein et al. #AACR24 Abst 2324 https://t.co/93Dw7se60g #LiquidBiopsy #PrecisionMedicine @TempusAI https://t.co/eMIkHUDmAp https://t.co/IE78IyYOH3
-
-
Mashup Score: 1Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy - Tempus - 3 month(s) ago
Background: Clonal Hematopoiesis (CH) is a well established confounder in next-generation sequencing (NGS)-based liquid biopsy cancer diagnostics. Misclassification of CH variants as tumor variants can lead to false positive actionable variant detection, potentially resulting in incorrect interpretation of results and therapy selection. Moreover, CH variants may also interfere with quantitative variant monitoring leading to inaccurate … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy [Mar 22, 2024] Sonnenschein et al. #AACR24 Abst 2324 https://t.co/93Dw7se60g #LiquidBiopsy #PrecisionMedicine @TempusAI https://t.co/eMIkHUDmAp https://t.co/IE78IyYOH3
-
-
Mashup Score: 2
Background: The frequency of HER2 expression in solid tumors other than breast (BC) and gastric cancer (GC) is not well defined. This study describes the frequency of HER2 expression by correlating HER2 IHC/ ISH and ERBB2 mRNA levels by NGS in tumor samples of patients with locally advanced/metastatic (LA/m) BC or GC and applying those findings … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Analysis of HER2 Prevalence by RNA Expression Across Solid Tumors [Mar 22, 2024] Moxley et al. @CharuAggarwalMD #AACR24 Abstract 5148 @CR_AACR @TempusAI https://t.co/ayCIqw4t2z #PrecisionMedicine https://t.co/FpTj12RNoI
-
-
Mashup Score: 0Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients - Tempus - 4 month(s) ago
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently … Continued
Source: www.tempus.comCategories: General Medicine News, General HCPsTweet-
.@TempusAI Launches Beta Version of olivia, its #AI-enabled Personal Health Concierge App for Patients - to empower individuals to holistically organize, manage, and proactively take control of their own health data | #generativeAI #PHR https://t.co/yPQhHKMack
-
-
Mashup Score: 1Tempus Announces Pricing of Initial Public Offering - Tempus - 8 month(s) ago
Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 per share. All of the shares of Class A common stock are being offered by Tempus. The gross proceeds to Tempus from the offering, before deducting … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Tempus Announces Pricing of Initial Public Offering https://t.co/dxOqsEddau
-
-
Mashup Score: 1Tempus Announces Pricing of Initial Public Offering - Tempus - 8 month(s) ago
Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 per share. All of the shares of Class A common stock are being offered by Tempus. The gross proceeds to Tempus from the offering, before deducting … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Tempus Announces Pricing of Initial Public Offering https://t.co/dxOqsEddau
-
-
Mashup Score: 0Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 9 month(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusAI
-
-
Mashup Score: 0Real-World Clinical Genomic Analysis of Patients with BRAF Mutated Cancers Identifies BRAF Class II and III as a Population of Unmet Medical Need - Tempus - 10 month(s) ago
Background Oncogenic BRAF mutations can be categorized into three classes (I, II and III) based on their distinct structural and signaling properties. BRAF inhibitors are approved in select cancer types for patients with Class I mutations. However, there are no approved targeted therapies for patients whose tumors bear BRAF Class II or III mutations. This … Continued
Source: www.tempus.comCategories: General Medicine News, Hem/OncsTweet-
Real-world clinical genomic analysis of Pts w/ BRAF mut cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson etal @ESMO TAT 2022 @TempusLabs https://t.co/s5PEBEczlv @Annals_Oncology DOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx https://t.co/m18RVCkTMF
-
Analysis of HER2 Prevalence by RNA Expression Across Solid Tumors [Mar 22, 2024] Moxley et al. @CharuAggarwalMD #AACR24 Abstract 5148 @CR_AACR @TempusAI https://t.co/ayCIqw4t2z #PrecisionMedicine https://t.co/FpTj12RNoI